Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 17/20 | 0.68 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL1829969 | 1.00 | TBXAS1 (0.68) | TBXAS1EGLN3KDM4EALDH1A1SMN1; SMN2 | |
| Bicarbonate SCHEMBL28296554 | 0.95 | TBXAS1 (0.70) | TBXAS1EGLN3 | |
| Pyruvate SCHEMBL27650226 | 0.93 | TBXAS1 (0.64) | TBXAS1EGLN3 | |
| Oxalic Acid SCHEMBL28223759 | 0.93 | TBXAS1 (0.80) | TBXAS1 | |
| Oxalic Acid SCHEMBL29575392 | 0.93 | TBXAS1 (0.80) | TBXAS1 | |
| Acetic Acid SCHEMBL16341977 | 0.93 | TBXAS1 (0.68) | TBXAS1EGLN3 | |
| Glycolic Acid SCHEMBL25294099 | 0.90 | TBXAS1 (0.64) | TBXAS1EGLN3ALDH1A1 | |
| Bicarbonate SCHEMBL28193995 | 0.89 | TBXAS1 (0.79) | TBXAS1EGLN3 | |
| Oxalic Acid SCHEMBL29142315 | 0.89 | EGLN3 (0.61) | TBXAS1EGLN3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL81565 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861364-B1 | PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION | C P PHARMACEUTICALS INTERNAT C V (US) | 2011-05-11 | — | — | EP | claimed |
| JP-2008533128-A | — | — | 2008-08-21 | — | — | JP | claimed |
| EP-1861364-A1 | PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION | Pfizer Science and Technology Ireland Limited (IE) | 2007-12-05 | — | — | EP | claimed |
| WO-2006097909-A1 | PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION | PFIZER SCIENCE AND TECHNOLOGY IRELAND LIMITED (IE) | 2006-09-21 | — | — | WO | claimed |
| EP-1861364-B1 | PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION | C P PHARMACEUTICALS INTERNAT C V (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-1861364-A1 | PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION | Pfizer Science and Technology Ireland Limited (IE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097909-A1 | PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION | PFIZER SCIENCE AND TECHNOLOGY IRELAND LIMITED (IE) | 2006-09-21 | — | — | WO | disclosed |
| EP-0000951-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING 1-SUBSTITUTED IMIDAZOLES, 1-SUBSTITUTED IMIDAZOLES AND 1-SUBSTITUTED IMIDAZOLES FOR USE IN THE TREATMENT OR PROPHYLAXIS OF THROMBO-EMBOLIC DISORDERS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-23 | — | — | EP | disclosed |
| US-4284641-A | ANTITHROMBOEMBOLIC AGENT | BURROUGHS WELLCOME CO. (US) | 1981-08-18 | — | — | US | disclosed |
| EP-0000951-A1 | Pharmaceutical Formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-03-07 | — | — | EP | disclosed |